Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies
- 1.6k Downloads
Concerns raised by several animal studies, case reports, and pharmacovigilance warnings over incretin-based therapy potentially exposing type two diabetes patients to an elevated risk of pancreatitis have cast a shadow on the overall safety of this class of drugs. This systematic review evaluates the data from observational studies that compared treatment with or without incretins and the risk of pancreatitis. We searched PubMed for publications with the key terms incretins or GLP-1 receptor agonists or DPP-4 inhibitors or sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin or exenatide or liraglutide AND pancreatitis in the title or abstract. Studies were evaluated against the following criteria: design (either cohort or case–control); outcome definition (incidence of pancreatitis); exposure definition (new or current or past incretins users); and comparison between patients receiving incretins or not for type 2 diabetes. Two authors independently selected the studies and extracted the data. Six studies meeting the inclusion criteria were reviewed. No difference was found in the overall risk of pancreatitis between incretin users and non-users (odds ratio 1.08; 95 % CI [0.84–1.40]). A risk increase lower than 35 % cannot be excluded according to the power calculation. This systematic review and meta-analysis suggests that type 2 diabetes patients receiving incretin-based therapy are not exposed to an elevated risk of pancreatitis. Limitations of this analysis are the low prevalence of incretin users and the lack of a clear distinction by the studies between therapy with DPP-4 inhibitors or with GLP-1 receptor agonists.
KeywordsIncretins Pancreatitis Observational studies Meta-analysis Type 2 diabetes
This study was supported by Chaira Medica Association (non-profit organization for the study of endocrine and metabolic disorders), Chieri, Italy; EN is employed with the Association.
Conflict of interest
CBG discloses teaching and speaking fees from Merck, Novo Nordisk, BMS/AZ Alliance, and BI/Lilly Alliance. All the other authors declare no conflicts of interest.
- 1.C.F. Deacon, E. Mannucci, B. Ahre´n, Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes. Obes. Metab. 14, 762–767 (2012)CrossRefPubMedGoogle Scholar
- 2.B. Gallwitz, Extra-pancreatic effects of incretin-based therapies. Endocrine (2014). doi: 10.1007/s12020-014-0223-0
- 3.N. Mikhail, Effects of incretin-based therapy in patients with heart failure and myocardial infarction. Endocrine 47(1), 21–28 (2014). doi: 10.1007/s12020-014-0175-4
- 4.J.A. Koehler, L.L. Baggio, B.J. Lamont, S.D. Ali, D.J. Drucker, Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes. 58, 2148–2161 (2009)CrossRefPubMedCentralPubMedGoogle Scholar
- 6.K. Tatarkiewicz, P.A. Smith, E.J. Sablan, C.J. Polizzi, D.E. Aumann, C. Villescaz, D.M. Hargrove, B.R. Gedulin, M.G.W. Lu, L. Adams, T. Whisenant, D. Roy, D.G. Parkes, Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am. J. Physiol. Endocrinol. Metab. 299, E1076–E1086 (2010)CrossRefPubMedCentralPubMedGoogle Scholar
- 11.J.L. Faillie, S. Babai, S. Crépin, V. Bres, M.L. Laroche, H. Le Louet, P. Petit, J.L. Montastruc, D. Hillaire-Buys, The French Pharmacovigilance Centers Network. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Acta Diabetol. 51(3), 491–497 (2014)Google Scholar
- 16.S.-W. Lai, C.-H. Muo, K.-F. Liao, F.-C. Sung, P.-C. Chen, Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: A population-based cohort study in Taiwan. Am. J. Gastroenterol. 106, 1697–1704 (2011)Google Scholar
- 22.B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, P. Hirshberg, R. Frederich, S.D. Wiviott, E.B. Hoffman, M.A. Cavender, J.A. Udell, N.R. Desai, O. Mosenzon, D.K. McGuire, K.K. Ray, L.A. Leiter, I. Raz, the SAVOR-TIMI 53 Steering Committee and Investigators, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369(14), 1317–1326 (2013)CrossRefPubMedGoogle Scholar
- 23.W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, A.T. Perez, P.R. Fleck, C.R. Mehta, S. Kupfer, C. Wilson, W.C. Cushman, F. Zannad, the EXAMINE Investigators, Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369(14), 1327–1335 (2013)CrossRefPubMedGoogle Scholar
- 27.M. Wenten, J.A. Gaebler, M. Hussein, E.M. Pelletier, D.B. Smith, P. Girase, R.A. Noel, D.K. Braun, G.L. Bloomgren, Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet. Med. 29(11), 1412–1418 (2012)CrossRefPubMedGoogle Scholar
- 31.S. Singh, H.Y. Chang, T.M. Richards, J.P. Weiner, J.M. Clark, J.B. Segal, Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA. Intern. Med. 173(7), 534–539 (2013)CrossRefPubMedGoogle Scholar
- 32.C.B. Giorda, R. Picariello, E. Nada, B. Tartaglino, L. Marafetti, G. Costa, R. Gnavi, Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. www.thelancet.com/diabetes-endocrinology. Accessed 12 Nov 2013. doi: 10.1016/S2213-8587(13)70147-5